Fill Out Your Profile to share more about you. Learn more...

Podcast: Trodelvy Offers Benefits for HR+ Breast Cancer

moderators
moderators Posts: 7,691

Trodelvy Offers Benefits for Hormone Receptor-Positive Breast Cancer
Sep 22, 2022

Dr. Hope Rugo discusses the latest results from the TROPiCS-02 trial showing Trodelvy improves overall survival compared to chemotherapy in metastatic, hormone receptor-positive, HER2-negative breast cancer.

At the European Society for Medical Oncology Congress 2022, Dr. Rugo presented results from the TROPiCS-02 trial, which was looking to see if the targeted therapy Trodelvy (chemical name: sacituzumab govitecan-hziy) could offer more benefits for people diagnosed with previously treated, metastatic, hormone receptor-positive, HER2-negative breast cancer than chemotherapy. Currently, Trodelvy is approved to treat previously-treated, metastatic triple-negative breast cancer.

Listen to the episode to hear Dr. Rugo explain:

  • the type of medicine Trodelvy is and how it works
  • the results showing people diagnosed with previously treated, metastatic, hormone receptor-positive, HER2-negative breast cancer lived longer when they received Trodelvy compared to chemotherapy
  • how the results from TROPiCS-02 fit into current treatment options
Listen now or read the transcript.